Lymphangioleiomyomatosis Clinical Trial
— TuScComOfficial title:
Biomarkers for Tuberous Sclerosis Complex: An International Multicenter Observational Longitudinal Protocol
Verified date | February 2023 |
Source | CENTOGENE GmbH Rostock |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
International, multicenter, observational, longitudinal study to identify biomarker/s for Tuberous Sclerosis Complex and to explore the clinical robustness, specificity, and long´-term variability of these biomarker/s
Status | Terminated |
Enrollment | 20 |
Est. completion date | December 30, 2022 |
Est. primary completion date | December 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 50 Years |
Eligibility | INCLUSION CRITERIA - Informed consent is obtained from the participant or from the parent / legal guardian - Participant is aged between 2 and 50 years - Diagnosis of TSC is genetically confirmed by CENTOGENE EXCLUSION CRITERIA - Inability to provide informed consent - Participant is younger than 2 or older than 50 years - Diagnosis of TSC is not genetically confirmed by CENTOGENE |
Country | Name | City | State |
---|---|---|---|
Albania | University Hospital Center Mother Teresa | Tirana | |
Egypt | Department of Pediatrics, Alexandria University Children's Hospital | Alexandria | |
Georgia | Departmnet of Molecular and Medical Genetics, Tbilisi State Medical University | Tbilisi | |
India | Department of Pediatric Genetics, Amrita Institute of Medical Sciences & Research Centre | Cochin | Kerala |
Lithuania | Rare diseases coordinating centre, Vilnius University Hospital Santaros klinikos | Vilnius | |
Pakistan | Departmnet of Pediatric Gastroenterology and Hepatology, The Children's Hospital and Institute of Child Health | Lahore | |
Romania | Emergency Hospital for Children "Louis Turcanu" | Timisoara | |
Sri Lanka | Lady Ridgeway Hospital for Children | Colombo |
Lead Sponsor | Collaborator |
---|---|
CENTOGENE GmbH Rostock |
Albania, Egypt, Georgia, India, Lithuania, Pakistan, Romania, Sri Lanka,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identification of TSC biomarker/s | All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC. | 36 months | |
Secondary | Exploring the clinical robustness, specificity, and longterm variability of TSC biomarker/s | Samples will be analyzed for the candidate biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC. | 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01687179 -
Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
|
Phase 1 | |
Completed |
NCT00366509 -
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
|
||
Completed |
NCT00552955 -
Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
|
||
Unknown status |
NCT00490789 -
Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
|
Phase 2 | |
Not yet recruiting |
NCT05087134 -
Characterizing LAM With 11C-Choline PET/CT
|
Early Phase 1 | |
Completed |
NCT02009241 -
Pulmonary Rehabilitation in Lymphangioleiomyomatosis
|
N/A | |
Recruiting |
NCT05190627 -
Effect of Loratadine in Lymphangioleiomyomatosis
|
Phase 2 | |
Completed |
NCT05323370 -
Lymphangioleiomyomatosis, a Study on Cathepsin K
|
||
Completed |
NCT02859194 -
The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients
|
N/A | |
Completed |
NCT01353209 -
Letrozole for Lymphangioleiomyomatosis
|
Phase 2 | |
Completed |
NCT03253913 -
Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
|
Phase 2 | |
Recruiting |
NCT02432560 -
Safety and Durability of Sirolimus for Treatment of LAM
|
||
Completed |
NCT02061397 -
Safety of Simvastatin in LAM and TSC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
Recruiting |
NCT04577937 -
Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis
|
N/A | |
Completed |
NCT00005906 -
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
|
Phase 2 | |
Recruiting |
NCT01799538 -
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
|
Phase 1/Phase 2 | |
Completed |
NCT00989742 -
Doxycycline In Lymphangioleiomyomatosis (LAM)
|
Phase 4 | |
Recruiting |
NCT06160310 -
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
|
||
Enrolling by invitation |
NCT05727852 -
Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
|